1 / 33

GAVI Support for Measles and Rubella Immunisation

GAVI Support for Measles and Rubella Immunisation. Helen Evans Deputy CEO, GAVI Alliance. 11 th Annual Meeting Measles & Rubella Initiative Washington D.C 18 September 2012. Overview. About the GAVI Alliance GAVI support to Measles & Rubella immunisation Communicating with Countries

hrichardson
Download Presentation

GAVI Support for Measles and Rubella Immunisation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. GAVI Support for Measles and Rubella Immunisation Helen Evans Deputy CEO, GAVI Alliance 11th Annual Meeting Measles & Rubella Initiative Washington D.C 18 September 2012

  2. Overview • About the GAVI Alliance • GAVI support to Measles & Rubella immunisation • Communicating with Countries • Advocacy

  3. The GAVI Alliance: an innovative partnership

  4. GAVI’s mission and four strategic goals Accelerate the uptake and use of underused and new vaccines Contribute to strengthening the capacity of integrated health systems to deliver immunisation Increase the predictability of global financing and improve the sustainability of national financing for immunisation Shape vaccine markets Mission: To save children’s lives and protect people’s health by increasing access to immunisation in poor countries

  5. What Countries have achieved with GAVI Alliance support Supported the immunisation of 326 million children Contributed to preventing over 5.5 million future deaths Accelerated vaccine introductions in over 70 countries Strengthened health systems to deliver immunisation Helped shape the market for vaccines Future deaths averted Source: These estimates and projections are produced by the WHO Department of Immunization, Vaccines and Biologicals, based on the most up-to-date data and models available as of 30 September 2011. *Includes deaths averted by GAVI-supported vitamin A supplementation programmes.

  6. Key GAVI policies • Country eligibility policy: • Threshold for 2012 is $1,520 GNI per capita (World Bank, Atlas method) – updated annually • Catalytic new vaccine introduction grant and operational support for campaigns policy – not recurrent operational support • Co-financing policy geared to programme ownership & financial sustainability In development: • Country-by-Country Approach: introducing more flexibility • Access to acceptable vaccine prices for lower middle income countries

  7. GAVI vaccines support

  8. GAVI supports the world’s poorest countries Type and value of support, 2000–2011 Source: GAVI Alliance , 2012

  9. GAVI cash-based support • GAVI supports health system strengthening (HSS) through the Health System Funding Platform • Focus on strengthening the capacity of integrated health systems to deliver immunisation outcomes • Resolve major constraints to delivery • Increase equity in access to services • Strengthen civil society engagement • New performance based approach being introduced • Countries and partners will be updated by end 2012

  10. GAVI vaccine introduction grant and operational support for campaigns policy – revised amounts from 1 Sept 2012 • Facilitate timely, effective implementation of critical activities: • Preparing for new vaccine introductions: US$ 0.80 per target (for HPV: US$ 2.40 per girl) • Supporting delivery of campaigns: US$ 0.65 per target • One-time investments, covering a share of the cost. Does not cover recurrent costs • Driven by country needs • Flexible, simple, separate from other cash support, not to be used for co-financing

  11. Overview • About the GAVI Alliance • GAVI support to Measles & Rubella immunisation • Communicating with Countries • Advocacy

  12. GAVI’s integrated commitents to prevent rubella and measles US$ 176 million from 2004-2008 through Measles Initiative to support campaigns Investments in health systems to improve immunisation coverage Routine measles second dose (11 countries receiving support, 3 more applied this year) Measles-rubella through wide-age campaigns and adoption of routine (9 countries have applied this year) Performance-based funding with measles coverage indicator

  13. Background and aim of increased GAVI engagement Estimated measles mortality has plateaued around 140,000 deaths Increased routine coverage critical to sustainably preventing measles Outbreaks possible (e.g. every 3–5 years) unless coverage is high GAVI support: Long-term strategy to prevent deaths in six countries through high routine coverage Bridging: help avoid further measles resurgence before and during the MR vaccine roll-out Outbreak prevention

  14. June 2012 GAVI Board decision on GAVI support for measles The GAVI Alliance will provide additional funding to control and prevent measles outbreaks US$ 55 million of this support will be for outbreaks and other emerging needs requiring rapid responses Six large countries at high risk of measles outbreaks (Afghanistan, Chad, DR Congo, Ethiopia, Nigeria and Pakistan) can exceptionally apply for GAVI support for preventive measles vaccination campaigns This support comes in addition to GAVI’s existing support for introducing the second dose of measles into routine immunisation

  15. GAVI support for rubella and measles vaccines

  16. GAVI support for rubella and measles vaccines

  17. GAVI support for rubella and measles vaccines

  18. The GAVI application and reporting cycle

  19. Overview • About the GAVI Alliance • GAVI support to Measles & Rubella immunisation • Communicating with Countries • Advocacy

  20. Overview of GAVI country communication • Maintaining an ongoing dialogue around GAVI policy, processes and vaccine evidence base • Information dissemination and feedback loops adapted to the content, context and audience • Written documents: guidelines, FAQs, briefs, letters, etc. Available at: http://www.gavialliance.org/support/apply/ • With countries and partners: • WHO/UNICEF in country and regional GAVI Alliance members • GAVI Secretariat CROs responsible for specific countries • Discuss new policy and technical developments • Consult and coordinate to resolve implementation bottlenecks

  21. Contact points for information

  22. Overview • About the GAVI Alliance • GAVI support to Measles & Rubella immunisation • Communicating with Countries • Advocacy

  23. What role does the GAVI Alliance play in advocating for immunisation? Objectives: • Position immunisation, global health and development in public policy agenda – value of investing in immunisation, new vaccines is understood amongst key influencers and stakeholders • Mobilize network of advocates and policy partners in countries and globally to inform policies, support fundraising and help achieve strategic goals of the Alliance • GAVI Alliance’s aim to be catalytic

  24. Advocacy building blocks GAVI Alliance became named partner of Measles & Rubella Initiative (August 2012)

  25. The immunisation landscape Synergies and shared learnings Measles elimination Polio eradication R&D: vaccine improvements New vaccines Traditional vaccines R&D: future vaccines Regional vaccines

  26. Thank you www.gavialliance.org

  27. Communication around the application cycle Dialogue with countries and partners to inform decision-making Dissemination of application guidelines, forms, other supporting information to countries and partners via email and web site, with specific follow up Coordination with partners for technical assistance and support in completing forms Updates on GAVI Alliance Board decisions and deliberations by email, media and multiple other channels. Countries contacted with information on IRC recommendations and any required clarifications The Board considers and approves IRC recommendations

  28. The Global Vaccine Action Plan Goals Guiding Principles Strategic objectives of the Decade of Vaccines • Achieve a world free of poliomyelitis • Meet global and regional elimination targets • Meet vaccination coverage targets in every region, country and community • Develop and introduce new and improved vaccines and technologies • Exceed the Millennium Development Goal 4 target for reducing child mortality Country ownership All countries commit to immunizations as a priority Individuals and communities understand the value of vaccines and demand immunization as both their right and responsibility Shared responsibility and partnership 2 4 3 1 5 6 Immunization programs have sustainable access to predictable funding, quality supply and innovative technologies Equity Strong immunization systems are an integral part of a well-functioning health system Integration The benefits of immunization are equitable extended to all people Sustainability Country, regional and global research and development innovations maximize the benefits of immunization Innovation Source: Bill & Melinda Gates Foundation

  29. June – Dec 2012 key events at a glance

  30. Session Chart 16:00 – 17:30 8:00 – 9:30 Plenary 1 9:00 – 13.00 Consultations and Satellite Events 14:30 – 16:00 10:00 – 11:30 Panel Panel GAVI Board Mtg Award Dinner Closing Session 12:30 – 14:00 Sessions Sessions Special Plenary 2 Special Lunch Lunch 13:30 – 15:30 Workshops Workshops 14:30 – 16:00 Panel 16:00 – 18:00 NM-GM Dialogue Workshops 16:30 - 17:30 18:30 – 20:30 18:30 – 21:00 Welcoming Ceremony by Tanzania government

  31. Aligning advocacy efforts • Partners’ Forum – themes focused around GVAP – measles and rubella sessions • World Immunisation Week • World Health Assembly and Regional Committees – reporting on progress • IPA Congress in Australia • GAVI Alliance mid-term review

More Related